HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Melrose Park, Ill. company announces it has closed the sale of its Indola European professional hair care business to Henkel in a transaction effective June 1. Although terms of the proposed agreement were not disclosed, the firm says it expects to realize a "small gain" of approximately $.05 per share on the sale in the third quarter ended June 30. Henkel announced it had reached an agreement in principle to purchase the brand in May (1"The Rose Sheet" May 10, 2004, p. 3)...

You may also be interested in...

Dial To Bring Henkel Technology To U.S. Personal Care Brands

Dial plans to enhance its personal care portfolio in North America by introducing Henkel formulas under the Dial brand name, Dial CEO Herb Baum said May 5 at a Henkel analyst meeting in New York City

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts